Veralox Therapeutics, a Frederick, Md.-based biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, closed a $16.6m Series A financing.
The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous investors Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO. In conjunction with the funding, Ben Scruggs, PhD, principal at Hatteras Venture Partners, and Jamie Stiff, MBA, managing director at Genesys Capital, will join the Veralox Therapeutics board of directors.
Investir | Amplitude complète son fonds médical de 200 millions
lapresse.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lapresse.ca Daily Mail and Mail on Sunday newspapers.
After Repare IPO success, Amplitude goes all in on Canadian life sciences sector with CA$200M fund
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.